FDA expands list of valsartan recalls

pharmafile | August 9, 2018 | News story | Medical Communications China, FDA, US, heart medication, recall, valsartan 

The US Food and Drug Administration (FDA) has expanded a list of products containing valsartan that are to be recalled.

The FDA announced an initial recall of drugs containing valsartan, which is used to treat high blood pressure and heart failure, in July of this year after it was discovered that some drugs could have been contaminated with carcinogenic substances. The drug had previously been recalled in 22 countries.

Drugs containing valsartan were found to have tested positive for N-nitrosodimethylamine (NMDA) which is considered a possible carcinogen by the U.S. Environmental Protection Agency. The contaminant is often a byproduct in certain manufacturing processes.

The FDA said in a statement that they are “working with drug manufacturers to ensure future valsartan active pharmaceutical ingredients (APIs) are not at risk of NDMA formation.”

It was further noted that “The agency reminds manufacturers to thoroughly evaluate their API manufacturing processes, and changes to those processes, to detect any unsafe impurities. If a manufacturer detects new or higher levels of impurity, they should take action to prevent changes to the product’s safety profile.”  

The recalled medicines have been linked to manufacturing facilities in the Zhejiang province in the east of China. The contaminated medicines were supplied by Zhejiang Huahai Pharmaceuticals who noted that they informed authorities as soon as they identified the impurity.

“We published our recall notice at midday on July 13 in China and overseas, and published the U.S. market recall notice on July 14 Beijing time … all the drug materials for the Chinese market were recalled by July 23,” the company said in a statement to the Shanghai stock exchange last month.

Louis Goss

Related Content

FDA grants ODD to Nexcella’s NXC-201 as treatment for amyloid light chain amyloidosis

Nexcella has announced that the US Food and Drug Administration (FDA) has granted orphan drug …

GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia

GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) …

Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA

Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for …

Latest content